Featured Articles
-
Collaboration An Untapped Fuel For Driving Biopharma R&D
10/20/2025
Biopharma’s future depends on collaboration. Discover how cross-industry partnerships and shared resources can accelerate innovation, overcome talent gaps, and strengthen the global R&D ecosystem.
-
Your Biosimilar, Your Journey
10/20/2025
With many blockbuster drug patents set to expire by 2030, the market is ripe for biosimilar developers to stake their claim. To succeed, they must be strategic and compliant.
-
A Risk-Based Approach To Plasmid DNA And mRNA Process Development
9/23/2025
Balancing robust analytics and clinical readiness is key for early-phase pDNA and mRNA therapeutics amid structural complexity and regulatory challenges.
-
Navigating The Regulatory Space To Biosimilar Approval
9/1/2025
The biosimilar patent cliff is reshaping pharma, creating unprecedented opportunities for biotech and CDMOs. Explore expert regulatory support that can help you navigate this shift with confidence.
-
Ready To Demystify Organoids?
7/1/2025
Organoids are transforming biomedical research. Explore their top applications, research workflows, key challenges, and dissociation techniques in this comprehensive guide to personalized medicine.
-
5 Key Considerations For Companies Outsourcing Process Development
6/9/2025
Venture capital in biotech remains strong post-pandemic, especially in cell and gene therapies. Discover five key factors to help companies choose between in-house and outsourced process development strategies.
-
Face The Unknown: Key Bispecific Antibody Discoveries
5/16/2025
Bispecific antibodies (BsAbs) are revolutionizing biopharmaceuticals with enhanced therapeutic potential. Learn how advanced design tools and expert support streamline BsAb development from concept to clinic.
-
Thunderstruck By Antibody-Drug Conjugates
3/18/2025
Antibody-drug conjugates are transforming cancer treatment by targeting tumors directly to reduce side effects. Discover how they affect neighboring cells, which can enhance treatment efficacy and eliminate tumor cell populations.
-
The Patent Cliff Looms – Design Your Biosimilar Approach Accordingly
3/3/2025
In your pursuit of developing a high-quality biosimilar, think strategically. Consider what type of biologic your team’s expertise can support and which is needed most in your target market.
-
Keeping The Momentum In Pandemic Preparedness
10/22/2024
Learn about the partnership between the Prairie HUB and Cytiva to create RNA vaccines to target potential pandemic viruses with the aim of redefining global pandemic preparedness.